| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.047 | 0.4 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | paclitaxel | CTRPv2 | pan-cancer | AAC | -0.027 | 0.4 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | AZ-3146 | CTRPv2 | pan-cancer | AAC | -0.028 | 0.4 |
| mRNA | PF-4800567 hydrochloride | CTRPv2 | pan-cancer | AAC | 0.044 | 0.4 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | FH535 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.4 |
| mRNA | vorapaxar | CTRPv2 | pan-cancer | AAC | -0.03 | 0.4 |